Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OWP-102
- Development stage
- Preclinical
- Lead developer
- OWP Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OWP-102 is an oral liquid small molecule formulation under development by OWP Pharmaceuticals for the treatment of psychiatric disorders. It is part of OWP's pipeline of reformulated, approved neuroscience therapeutics designed to provide alternative liquid delivery options for pediatric, adolescent, and other patient populations who have difficulty swallowing solid oral dosage forms. The specific active pharmaceutical ingredient and molecular target of OWP-102 have not been publicly disclosed, but the candidate is being developed via the FDA's 505(b)(2) regulatory pathway.
Beyond the preview
Go deeper on OWP-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OWP-102.